International Journal of Science and Healthcare Research
Vol.5; Issue: 3; July-Sept. 2020
Website: ijshr.com
Review Article *ISSN: 2455-7587*

Polycystic Ovary Syndrome (PCOS): Current and Future Therapy

Maged MN[1], Mohamed MN[2], Lamia H.Shehata[3]

[1]Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia.
[2]Department of Ob/Gyn, King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia.
[3]Department of Surgery, Care National Hospital, Kingdom of Saudi Arabia.

Corresponding Author: Maged MN

ABSTRACT

Polycystic ovary syndrome (PCOS) is a multifaceted condition portrayed by constant anovulation and excess ovarian activity, as opposed to different reasons for anovulation that include ovarian lethargy or essential inadequacy. Ongoing examinations showed that PCOS is related with second rate ceaseless aggravation and that women with PCOS are at expanded danger of non-alcoholic fatty liver disease. The inflammatory and metabolic disturbances related with PCOS are clarified to some extent by the conjunction of insulin resistance and obesity however are additionally filled by the androgen abundance. New bits of knowledge into the guideline of hormones and cytokines in muscle and fat tissue bolster the idea that PCOS is a foundational condition. The therapeutic arrangement ought to be customized to the patient phenotype, complaints, and reproductive desire. Of note, the aromatase inhibitor letrozole is by all accounts more powerful than the reference medicate clomiphene citrate to treat barrenness due to PCOS. Fundamental administration by a multidisciplinary team may help the patients to adhere to lifestyle interventions and in this way lessen body adiposity and recuperate their metabolic and reproductive health.

Key words: Polycystic ovary syndrome, PCOS, insulin resistance, infertility, menstrual irregularity

INTRODUCTION

Polycystic ovary condition (PCOS) is the most widely recognized endocrine issue in women, giving a few potential mixes of signs and manifestations, which may incorporate conceptive, endocrine, and metabolic adjustments. PCOS is portrayed by hypothalamic–pituitary–ovary axis dysfunction and anovulation in any case, dissimilar to different reasons for ovulatory failure that highlight inadequate ovarian follicle development or suppressed gonadotropin secretion (or both), PCOS commonly incorporates androgen overabundance and inconspicuous adjustments (not identified by routine tests) in serum levels of gonadotropins and estrogens. PCOS has the potential for serious outcomes, including expanded hazard for the advancement of endometrial hyperplasia and neoplasia (1). Moreover, extra-conceptive appearances of PCOS incorporate insulin resistance (IR), metabolic syndrome (MS), and low-grade chronic inflammation (2–6).

Lately, numerous advances have been made in the under-remaining of pathophysiological components and subsequently in the diagnosis and the management of PCOS.

Advances and difficulties in PCOS understanding The Rotterdam Consensus, held mutually by the European and the North American relationship of regenerative medication in 2003, characterized the diagnostic rules of PCOS which remain the most utilized worldwide for both individual analysis and research. It characterized PCOS as the nearness of any two of three highlights: hyperandrogenism (clinical or

biochemical), ovulatory dysfunction (menstrual abnormalities), and polycystic ovarian morphology (PCOM) by ultrasound. The syndrome is a finding of exclusion that ought to be built up simply after assessment of different reasons for anovulation or androgen abundance (or both): hypogonadism, hypo-or hyperthyroidism, hyperprolactinemia, 21-hydroxylase deficiency, Cushing's condition, and androgen-creating tumors(7). In spite of some contention about the suitability of the Rotterdam rules to manage PCOS medicines, their utility to anticipate regenerative results is well established (8). An ongoing rule from the International PCOS Network suggested utilization of the Rotterdam measures in grown-ups and the necessity of both oligo-anovulation and hyperandrogenism for PCOS analysis in adolescents(9).

There are a few mixes of signs and symptoms that might be represented in the diagnosis of PCOS, bringing about various phenotypes for a similar syndrome. To all the more likely comprehend the pathogenesis of the disorder, it is critical to analyze the genetic profiles of women whose finding depended on the various phenotypes. An ongoing genome-wide meta-investigation from more than 10,000 PCOS cases distinguished 14 free loci related with the hazard for PCOS, including three novel loci (10). This huge scope study found no contrast between the different clinical phenotypes for the relationship with the greater part of the PCOS susceptibility loci, proposing that normal genetic traits may underlie the different phenotypes.

Hyperandrogenism is a significant clinical characteristic of the condition since it is related with more worse prognosis and higher risk of metabolic and cardiovascular disease (11). Be that as it may, late genetic discoveries recommend that it may not be the main driver of PCOS manifestations (10,12). As analyzed by the Rotterdam rules, hyperandrogenism is available in around 60 to 80% of cases. Biochemical hyperandrogenism stays an analytic test in light of the fact that the test strategies are inadequately normalized, there are no general shorts for conclusion, and a few measures with the expectation of complimentary testosterone evaluation are unreliable(13,14). In this manner, until a delicate, reproducible, and broadly approved testosterone test opens up and reasonable for clinical practice, the evaluation of biochemical hyperandrogenism to affirm or discard PCOS ought to depend on complete serum testosterone, sex hormone–binding globulin (SHBG), and free androgen index using local cutoffs(13,15).

Anti-Müllerian hormone (AMH) is a glycoprotein emitted by the granulosa cells of pre-antral and small antral follicles. AMH assumes a fundamental role in sexual differentiation and gonadal function, other than focal consequences for the hypothalamic–pituitary–gonadal axis. A direct test study showed that AMH receptor is communicated in gonadotropin-releasing hormone (GnRH) neurons and that intra cerebroventricular organization of AMH expands GnRH-subordinate luteinizing hormone (LH) pulsatile release (16). There is collecting proof that GnRH pulsatility is perturbid in women with PCOS, prompting expanded LH pulsatility, which plays a significant role in PCOS pathophysiology.(17) Serum AMH levels are ordinarily expanded in PCOS(18), and subsequently AMH-subordinate guideline of GnRH discharge could be associated with the patho-physiology of richness in women with PCOS.(16)

I. Metabolic profile

IR is so regular in PCOS that it very well may be viewed as an indispensable part of the syndrome. IR and glucose metabolism deregulation are right now expected to assume a pathogenic role in the disease. IR prompts compensatory hyperinsulinemia, which increments ovarian androgen synthesis both by direct ovarian activities and by animating LH secretion.(3) IR likewise actuates dyslipidemia, and women with PCOS have an expanded risk

of type(2) diabetes mellitus and cardiovascular disease .(5)

Another expected metabolic inconvenience of PCOS is non-alcoholic fatty liver disease (NAFLD), characterized as hepatic steatosis is not clarified by alcohol or other specific etiologic agents. NAFLD is mechanistically and epidemiologically connected to obesity, IR, and MS(19). PCOS is related with expanded risk of NAFLD paying little heed to the nearness of heftiness, proposing that the connection among PCOS and NAFLD is likewise clarified by different highlights of PCOS, for example, IR and androgen abundance. Truth be told, a deliberate audit and meta-investigation demonstrated a higher predominance of NAFLD among women with hyperandrogenic PCOS contrasted and different phenotypes of the disorder, while serum androgen levels were higher in PCOS women with NAFLD contrasted and PCOS ladies without NAFLD.(20)

Adipokines and inflammation go betweens discharged by the fat tissue likewise add to the metabolic modifications found in PCOS(6) Furthermore, various development elements, cytokines, and receptive oxygen species delivered by the ovaries, liver, and different tissues make a condition of interminable inflammation that agrees to keep up the metabolic awkwardness of the syndrome(4,6)

During the previous decade, skeletal muscle has likewise been recognized as a secretory organ that releases cytokines and different peptides, called myokines. Irisin has been distinguished as an exercise induced myokine and has been proposed to intercede the valuable impacts of activity on metabolism (21). Irisin can incite an adjustment in attributes of white adipocytes that secure a "brown" phenotype. This change incorporates the initiation of uncoupling protein 1 (UCP-1), prompting expanded breath and vitality expenditure (21,22) Irisin is additionally delivered at lower sums outside the skeletal muscle(23). Mind inferred Irisin intercedes anxiolytic impacts of vigorous exercise (24) and shields the cerebrum from synaptic and cognitive decline in a creature model of Alzheimer's disease (25). Moreover, in vivo irisin imbuement improves bone mass and engineering in youthful male mice (23).

The declaration of Irisin is emphatically connected with body mass index (BMI) and muscle mass, and Irisin metabolism is abnormal in patients with type 2 diabetes or gestational diabetes (26). Serum Irisin levels were related with hyperandrogenism yet not with oligovulation or PCOM in women with PCOS(27). After modification for BMI, patients with PCOS appear to have typical Irisin levels; in any case, Irisin reaction to hyper insulinemia may be impaired in patients with PCOS(28).

It is dubious whether PCOS is some way or another related with low serum levels of nutrient D. A precise audit discovered 12 studies with heterogeneous outcomes and their meta-investigation proposed lower serum 25-(OH) D in PCOS versus controls yet no distinctions in serum 1,25 (OH) D between the two groups(29). All the more critically, if a woman with PCOS has nutrient D insufficiency, she will be at expanded risk of metabolic comorbidities. Nutrient D supplementation may lessen ceaseless inflammation markers in women with PCOS and nutrient D deficiency (30,31), yet there is no proof that such treatment improves the metabolic status of patients(29)

Polycystic ovarian morphology (PCOM) and the finding of PCOS, PCOM is one of three models for determination of PCOS. PCOM is characterized as follicle number, be that as it may, the most recent age of ultrasound gadgets (maximal test frequencies that surpass 8 MHz) is increasingly delicate and yields a bigger follicle include in everybody; in this manner, the current utilization of the old cutoff can overestimate the commonness of PCOM(32). A gathering of specialists as of late proposed the utilization of higher in-house edges (that is, 19 to 25 follicles for

each ovary) to characterize PCOM with the new ultrasound machines (33).

Serum AMH levels associate with follicle number in women with PCOS. A few investigations found a decent concordance between serum AMH levels and ultrasound results for the determination of PCOM. These investigations propose that serum AMH could be an intermediary for ovarian follicle count and an elective marker of PCOM to be utilized reciprocally with ultrasound relying upon serum AMH and ovarian follicle check availability (34). Ongoing investigations show that elevated levels of AMH (>35 pmol/L) have a decent connection with the finding of PCOM at ultrasound (34). In any case, serum AMH levels ought not yet be utilized as a marker or as a solitary test for the analysis and recognition of PCOS (9, 33).

II. PCOS at various phases of life

An investigation thought about clinical and biochemical boundaries of PCOS in women and controls that visited a clinical focus at a mean age of 29 years and returned 6 years after the fact all things considered. Maturing was related with an expansion in the quantity of standard menstrual cycles, a diminishing in serum androgen levels, and decrease in IR(18). The explanations behind this attenuation of PCOS highlights after some time are not satisfactory. Different examinations have concentrated on PCOS appearances in specific age gatherings, as detailed below.

PCOS in childhood: The communication between a genetic inclination and some pre-birth and postnatal ecological variables appears to partake in the pathophysiology of PCOS. Intrauterine development hindrance or little for gestational age (or both) and elevated levels of androgens during the intrauterine period could prompt an expanded creation of glucocorticoids which may initiate epigenetic alterations and increment the hazard of PCOS (35).

PCOS in adolescence: Menstrual irregularity, acne, and hirsutism are the significant discoveries in this age gathering. Be that as it may, these highlights of PCOS cover with those of ordinary adolescence. Family history of PCOS, overweight or low birth weight, exposure to androgens during gestation, precautious puberty, obesity, and IR are hazard factors that are identified with the advancement of the disorder. The determination of PCOS during adolescence depends on stricter rules than in adult women. It requires unequivocal hyperandrogenism (for instance, moderate to extreme hirsutism or persevering height of serum testosterone levels or both) and ovulatory dysfunction that continues for more than 2 years after menarche (36).

Ongoing examinations indicated that adolescents with PCOS have expanded danger of MS and ought to be encouraged to embrace a sound way of life at once (37). At the point when an analysis of PCOS has been built up, the chance of IR signs and quality of life issues ought to be thought of. Weight, overweight, and hyperinsulinemia might be available in young people. Furthermore, dietary issues (bulimia, anorexia, and voraciously consuming food) and deficient weight control plans with a lot of hyper caloric and industrialized nourishments are common in adolescence. Dietary direction, incitement to physical action, and self-care ought to be a piece of the indispensable consideration for adolescence girls.

PCOS in postmenopausal women endure with hyperandrogenism much after menopausal progress and keep on showing metabolic adjustments and MS with expanded danger of cardiovascular sickness. Consequently, postmenopausal women with a past history with PCOS during the conceptive years may in any case have indications of the syndrome (9, 38).

Researchers have examined other therapeutic measures, for example, foundational microorganism treatment, for infertility. Stem cells are undifferentiated cells with the capacity to restore themselves

for extensive stretches without critical changes in their general properties. They can separate into different particular cell types under certain physiological or experimental conditions. Because of the restrictions of utilizing embryological and induced pluripotent stem cells, there is incredible enthusiasm for mesenchymal stem cells (MSCs), which are free from both moral concerns and teratoma formation (39).

MSCs, additionally called mesenchymal stromal cells, are a subset of non hematopoietic adult stem cells that begin from the mesoderm. They have self-renewal capacities and multilineage separation into not just mesoderm heredities, for example, chondrocytes, osteocytes, and adipocytes, yet additionally ectodermic and endodermic cells (40-42). MSCs can be gathered from a few grown-up tissues, for example, bone marrow, menstrual blood, fat tissue, the umbilical string, and placenta (43-47).

DISCUSSION

Treatment of PCOS ought to be proposed not exclusively to lighten indications yet additionally to forestall the event of long term complications. Joined oral contraceptives and anti androgens is the standard consideration to decrease androgen levels and treat symptoms while giving endometrial protection (48). Notwithstanding, the therapeutic arrangement ought to be custom-made relying upon the longing (or not) of the patient to get pregnant, requirement for tasteful methodology, and the nearness of associative metabolic adjustments.

The general objectives of treatment of women with PCOS incorporate the moderation of hyper androgenic manifestations, the executives of metabolic variations from the norm and decrease of hazard factors for type 2 diabetes and cardiovascular ailment, counteraction of endometrial hyperplasia, arranging and acquiring a safe pregnancy whenever wanted, and improving general prosperity and personal satisfaction.

1. Metabolism

The first line of treatment in quite a while with PCOS ought to be the improvement in way of life. In overweight and obese, weight reduction because of changes in diet and physical movement diminishes serum insulin and androgen levels and decreases the risk of creating glucose intolerance and type 2 diabetes. Pharmacological mediations are shown within the sight of IR/glucose narrow mindedness or dyslipidemia that continue after way of life modifications (39).

Metformin is the most generally utilized medication for the metabolic control of these patients (49). The restorative impacts of metformin as insulin-sharpening and hypoglycemic agent have been very well confirmed in l women with PCOS (50). Be that as it may, in spite of what is usually accepted or what observational uncontrolled examinations suggest (49), there is no persuading proof that metformin lessens BMI in women with PCOS compared and placebo (50). The expansion of metformin may have negligible advantage on the BMI of women who get antiandrogen and joined oral contraceptive (39). Metformin doesn't appear to diminish body adiposity as it has nearly nothing if any impact on decreasing waist circumference and serum triglyceride levels in women with PCOS (50).

Current examinations are investigating the theory that genomic variations characterize the responsiveness to metformin treatment among women with PCOS (51). Since Metformin frequently has gastrointestinal symptoms, new pharmaceutical arrangements particularly intended for vaginal delivery are a work in progress thus far has been powerful in a preclinical model of PCOS (52).

Liraglutide is a glucagon-like peptide receptor 1 agonist endorsed for rewarding kind 2 diabetes and stoutness. In obese women with PCOS, liraglutide was viable to actuate critical weight reduction

and decrease waist f circumference (53). Orlistat is a lipase inhibitor named for treatment of weight loss. In overweight or corpulent women with PCOS, Orlistat is powerful to initiate weight reduction and improve clinical and biochemical markers of hyperandrogenism and IR (54).

Myo-and D-chiro-inositol are insulin-sensitizing agents that go about as second flag-bearers in insulin flagging. These mixes have been assessed as potential options in compared to metformin in PCOS women with IR. Inositol isoforms mediate insulin action in many target organs, including the ovary (55). In a mouse model of PCOM actuated by steady light introduction, the theca/ granulosa cell layer thickness proportion and the opportunity to pregnancy were decreased by treatment with myo-inositol and D-chiro-inositol in a 40:1 molar ratio (56).

Prior clinical investigations without a placebo treatment or metformin demonstrated an a decrease in serum testosterone alongside an increase in SHBG levels following 6month of treatment with myo-inositol alone or related with D-chiro-inositol (57) and no distinction between D-chiro-inositol alone or joined with myo-inositol on the quantity of develop oocytes recovered for in vitro preparation (IVF)(58). A late meta-examination presumed that myo-inositol supplementation for IVF didn't improve oocyte or embryo quality(59).

Given the current body of evidence, we accept that inositol treatment may turn into an option for metabolic improvement of PCOS women who don't endure metformin, yet information with a vis-à-vis correlation among inositols and metformin are as yet absent. Three little, single-focus randomized controlled examinations distributed in 2017 tended to this inquiry and discovered better outcomes with either myo-inositol (60) or metformin (61) or comparative advantages with the two drugs (62). As indicated by the Inter-national PCOS Network, inositol (in any structure) ought to be viewed as an experimental treatment in PCOS (9).

2. Quality of life

PCOS shows in women at reproductive age when issues, for example, finding an accomplice, and framing a family are frequently pertinent. Variables that contrarily affect personal satisfaction Elements that adversely influence physical appearance or womanliness or bargain ripeness are wellsprings of incredible uneasiness (63).

The psychological effect of PCOS may even outperform that of chronic diseases, for example, asthma, diabetes, joint inflammation, and coronary heart disease (64).

Depression and anxiety are exceptionally common in women with PCOS, with a fourfold increment in the depression symptoms side effects in patients with the condition when compared with controls, even after change the BMI (65). Day by day weakness and rest issues, changes in hunger, and loss of enthusiasm for regular exercises were the most widely recognized symptoms (66). Accordingly, the assessment of personal satisfaction in women with PCOS is fundamental for better care and clinical management of these patients.

3. Infertility

In overweight or obese patients with PCOS who wish to conceive, life style changes focused on weight reduction ought to be the achievement of previously established inclination directing. Loss of 5 to 7% of body weight might be successful to advance menstrual cycle regularization and spontaneous ovulation (39). On the off chance that the woman can't get thinner or doesn't re-establish ovulatory cycles, treatment ought to be individualized while considering duration of infertility, the woman's age, and the risks of pregnancy at that age, and the factors that might be related to her difficulty to lose weight. Preconception care incorporates folic acid supplementation at a dose of 0.4 mg/day and cessation of smoking and alcohol consumption.

The second line of treatment (after life style interventions) is ovulation induction. This progression must be gone with careful evaluation of different reasons for infertility, for example, male factor or tubal obstruction, which request IVF and may exist together with PCOS.

Clomiphene citrate (CC) is the reference therapy for ovulation induction in an ovulatory woman with PCOS. Without ovulation for three cycles of CC at the highest dose (150 mg/day), the woman can be considered non-responsive and another medication ought to be presented as an adjuvant or substitute for CC.

Compared and placebo treatment, metformin lessens serum testosterone levels and increases the frequency of spontaneous ovulation and regular menstrual cycles in patients with PCOS (51). Be that as it may, in light of the fact that it accomplishes lower live birth rates compared with CC, metformin is no longer prescribed to induce ovulation (50, 67).

Besides, there is no conclusive proof about whether the relationship of metformin with CC varies from CC alone in live birth rates. the addition of metformin to CC increases the ovulation and clinical pregnancy rates but also, the miscarriage rate compared to CC alone(50,68). In women resistant to CC, limited proof recommends that adding metformin may increase the pregnancy rate (67). Maintaining metformin during gestation doesn't appear to prevent unfavorable outcomes (50, 67, 69, and 70)
Also, may in fact increase the risk of future overweight in offspring (71).

The aromatase inhibitor letrozole at a dose of 2.5 mg/day might be utilized as a choice to induce ovulation in patients who have failed to respond to CC. numerous examinations recommend that letrozole can be utilized as first-line treatment in ovulation induction however this utilization stays off-name. The dose might be increased by 2.5 mg/day to a limit of 7.5 mg/day. The major advantage of letrozole over CC is better ovulation-induction response, particularly in obese patients, which translates into higher pregnancy and live birth rates (68, 72). Fundamental information additionally proposes that letrozole is better than metformin in addition to CC to induce ovulation as evaluated by the clinical pregnancy rate in randomized clinical trial (73).

If there is failure of oral ovulation inducers, injectable gonadotropins combined with coordinated intercourse, intrauterine insemination, or IVF might be utilized. The addition of metformin to gonadotropins has given some advantage in low-complexity treatment (coordinated intercourse or intrauterine insemination) however not in IVF (70, 74). Fundamental outcomes propose that liraglutide at low dose can assist with improving the result of IVF treatment in obese women with PCOS (75).

Women with PCOS should be advice about the most fortunate second for pregnancy, considering the obstetric, metabolic, and cardiovascular risks that might be available. Along these lines, safe contraception is a piece of the essential care(76)as it permits delaying pregnancy while implementing life style interventions to lose fat mass and improve the metabolic homeostasis so as to get a pregnancy as well as a fruitful full-term pregnancy with both mother and baby healthy.

Future Perspectives

MSCs have exhibited incredible potential and accessibility for rewarding female infertility in animal and human studies. Autologous adipose derived stem cells are particularly helpful on the grounds that they are effectively acquired, and avoid graft rejection after transplantation. In ongoing decades, autologous adipose derived stem cells transplantation or infusion have demonstrated constructive outcomes on rodent models can expand treatment rates. Be that as it may, there are a few primary bearings for utilizing MSC to treat infertile women caused by ovarian or uterine factors: (1) Most examinations have

been done on little animals, and there is a genuine absence of significant exploration in large animals models that all the more intently emulate the ovarian or endometrial pathophysiology of human female infertility. Moreover, randomized controlled trials ought to be led to affirm the therapeutic impact of MSCs in fertility medication. (2) The mechanism of MSCs in treating dysfunction of female reproductive organs is as yet obscure. Possibilities include promoting angiogenesis, differentiating into functional cells, and a paracrine system. Among these, a paracrine system may be the most significant for female infertility treatment. Be that as it may, useful paracrine factors stay obscure and different systems might be synergistic. (3) While MSC treatment is promising, the limited survival and engraftment of bioactive operators because of a hostile environment is a bottleneck for disease treatment.

CONCLUSION

New insights into the cross-talk between muscle, fat, brain, and ovary tissue support the concept that PCOS is a systemic syndrome. The classic reproductive and dermatological features of PCOS are just the visible part of a more complex mechanism. The inflammatory and metabolic derangements associated with PCOS are explained in part by the coexistence of IR and obesity but are further fuelled by the androgen excess. The therapeutic plan should be tailored to the patient phenotype, complaints, and reproductive desire. Medical treatments have not seen any breakthrough in recent years. Of note, the aromatase inhibitor letrozole seems to be more effective than the reference drug CC to treat infertility due to PCOS. Integral management by a multidisciplinary team may help patients to adhere to lifestyle interventions and thereby reduce body adiposity and recover their metabolic and reproductive health.

Furthermore, a randomized controlled trial should be conducted to confirm the therapeutic effect of MSCs in fertility medicine. (2) The mechanism of MSCs in treating dysfunction of female reproductive organs is still unknown. Possibilities include promoting angiogenesis, differentiating into functional cells, and a paracrine mechanism. Among these, a paracrine mechanism might be the most important for female infertility treatment. However, beneficial paracrine factors remain unknown and multiple mechanisms may be synergistic. (3) While MSC therapy is promising, the limited survival and engraftment of bioactive agents due to a hostile environment is a bottleneck for disease treatment.

Conflict of interest

All authors declare no conflicts of interest.

Authors' contribution

Authors have equally participated and shared every item of the work.

REFERENCES

1. Barry JA, Azizia MM, Hardiman PJ: Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic reviewandmeta-analysis. *Hum Reprod Update.* 2014; 20(5):748–58.
2. Çakıroğlu Y, Vural F, Vural B: The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. *J EndocrinolInvest.* 2016; 39(8): 899–907.
3. de Leo V, Musacchio MC, Cappelli V, *et al.*: Genetic, hormonal andmetabolic aspects of PCOS: an update. *ReprodBiolEndocrinol.* 2016; 14(1): 38.
4. Durmus U, Duran C, Ecirli S: Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. *J Endocrinol Invest.* 2017; 40(5): 487–97.
5. McCartney CR, Marshall JC: Clinical Practice. Polycystic Ovary Syndrome. *N Engl J Med.* 2016; 375(1): 54–64.
6. Spritzer PM, Lecke SB, Satler F, *et al.*: Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in

polycystic ovary syndrome. *Reproduction.* 2015; 149(5):R219–R227.
7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *FertilSteril.* 2004; 81(1):19–25.
8. Wang R, Mol BW: The Rotterdam criteria for polycystic ovary syndrome: evidence-based criteria? *Hum Reprod.* 2017; 32(2): 261–4.
9. Teede HJ, Misso ML, Costello MF, *et al.*: Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Hum Reprod.* 2018; 33(9):1602–18.
10. Day F, Karaderi T, Jones MR, *et al.*: Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. *PLoS Genet.* 2018; 14(12):e1007813.
11. Daan NM, Jaspers L, Koster MP, *et al.*: Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features. *HumReprod.* 2015; 30(10): 2376–86.
12. Dumesic DA, Oberfield SE, Stener-Victorin E, *et al.*: Scientific Statement on the DiagnosticCriteria,Epidemiology,Pathophysiology,andMolecularGeneticsof Polycystic Ovary Syndrome. *EndocrRev.* 2015; 36(5):487–525.
13. Legro RS, Arslanian SA, Ehrmann DA, *et al.*: Diagnosis and treatment of polycysticovary syndrome: an Endocrine Society clinical practice guideline. *J Clin EndocrinolMetab.* 2013; 98(12):4565–92.
14. Wierman ME, Arlt W, Basson R, *et al.*: Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. *J ClinEndocrinolMetab.* 2014; 99(10):3489–510.
15. Mario FM, Graff SK, Spritzer PM: Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS: a cross- sectional study. *J Endocrinol Invest.* 2017; 40(4):377–84.
16. Cimino I, Casoni F, Liu X, *et al.*: Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. *Nat Commun.* 2016; 7: 10055.
17. Katulski K, Podfigurna A, Czyzyk A, *et al.*: Kisspeptin and LH pulsatile temporal coupling in PCOS patients. *Endocrine.* 2018; 61(1):149–57.
18. Brown ZA, Louwers YV, Fong SL, *et al.*: The phenotype of polycystic ovary syndrome ameliorates with aging. *FertilSteril.* 2011; 96(5): 1259–65.
19. Mishra A, Younossi ZM: Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. *J ClinExpHepatol.* 2012; 2(2):135–44.
20. Rocha ALL, Faria LC, Guimarães TCM, *et al.*: Non-alcoholic fatty liver disease in womenwithpolycysticovarysyndrome:systematicreviewandmeta-analysis. *J Endocrinol Invest.* 2017; 40(12):1279–88.
21. Boström P, Wu J, Jedrychowski MP, *et al.*: A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature.* 2012; 481(7382): 463–8
22. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, *et al.*: Irisin in metabolic diseases. *Endocrine*. 2018; 59(2):260–74.
23. Colaianni G, Cuscito C, Mongelli T, *et al.*: The myokineirisinincreases cortical bone mass. *ProcNatlAcadSci U S A.* 2015; 112(39):12157–62.
24. Uysal N, Yuksel O, Kizildag S, *et al.*: Regular aerobic exercise correlates with reduced anxiety and increased levels of irisin in brain and white adipose tissue. *NeurosciLett.* 2018; 676: 92–7.
25. Lourenco MV, Frozza RL, de Freitas GB, *et al.*: Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models. *Nat Med.* 2019; 25(1): 165–75.
26. Moreno-Navarrete JM, Ortega F, Serrano M, *et al.*: Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. *J ClinEndocrinol*
27. Zhang L, Fang X, Li L, *et al.*: The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. *J Endocrinol Invest.* 2018; 41(12): 1401–7.
28. Cai X, Qiu S, Li L, *et al.*: Circulating irisin in patients with polycystic ovary syndrome: a meta-analysis. *Reprod Biomed Online.* 2018; 36(2): 172–80.
29. He C, Lin Z, Robb SW, *et al.*: Serum Vitamin D Levels and Polycystic Ovary

syndrome: A Systematic Review and Meta-Analysis. *Nutrients.* 2015; 7(6): 4555–77.
30. Foroozanfard F, Jamilian M, Bahmani F, *et al.*: Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial. *ClinEndocrinol (Oxf).* 2015; 83(6): 888–94.
31. Irani M, Seifer DB, Grazi RV, *et al.*: Vitamin D Supplementation Decreases TGF- β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial. *J ClinEndocrinolMetab*. 2015; 100(11):4307–14.
32. MartinsWP,KollmannM,Raine-FenningN: Countingovarianfollicles:updated threshold for diagnosis of hyperandrogenic anovulation. *Ultrasound Obstet Gynecol.* 2014; 44(2): 131–4.
33. Dewailly D, Lujan ME, Carmina E, *et al.*: Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. *Hum Reprod Update.* 2014; 20(3): 334–52.
34. Fraissinet A, Robin G, Pigny P, *et al.*: Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. *Hum Reprod.* 2017; 32(8): 1716–22.
35. Bellver J, Rodríguez-Tabernero L, Robles A, *et al.*: Polycystic ovary syndrome throughout a woman's life. *J Assist Reprod Genet.* 2018; 35(1): 25–39. |
36. Witchel SF, Oberfield S, Rosenfield RL, *et al.*: The Diagnosis of Polycystic Ovary Syndrome during Adolescence. *Horm Res Paediatr*. 2015; 83: 376–389.
37. Fitzgerald S, DiVasta A, Gooding H: An update on PCOS in adolescents. *CurrOpinPediatr*. 2018; 30(4):459–465.
38. Shah D, Bansal S: Polycystic ovaries - beyond menopause. *Climacteric*.2014;17(2): 109–15.
39. Blum B., Benvenisty N. The tumorigenicity of human embryonic stem cells. *Advances in Cancer Research*. 2008;100(8):133–158. doi: 10.1016/S0065-230X(08)00005-5.
40. Luque-Ramírez M, Nattero-Chávez L, Ortiz Flores AE, *et al.*: Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update.* 2018; 24: 225–41.
41. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8(4):315–317
42. Dezawa M., Ishikawa H., Itokazu Y., et al. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. *Science*. 2005;309(5732):314–317
43. Salem H. K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. *Stem Cells*. 2010;28(3):585–596
44. Körbling M., Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? *Blood*. 2001;98(10):2900–2908
45. Meng X., Ichim T. E., Zhong J., et al. Endometrial regenerative cells: a novel stem cell population. *Journal of Translational Medicine*. 2007;5(1):1–10.
46. Barry F. P., Murphy J. M. Mesenchymal stem cells: clinical applications and biological characterization. *The International Journal of Biochemistry & Cell Biology*. 2004;36(4):568–584
47. Lee O. K., Kuo T. K., Chen W.-M., Lee K.-D., Hsieh S.-L., Chen T.-H. Isolation of multipotentmesenchymal stem cells from umbilical cord blood. *Blood*. 2004;103(5):1669–1675.
48. in't Anker P. S., Scherjon S. A., der Keur C. K.-v., et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *Stem Cells*. 2004;22(7):1338–1345
49. Balen AH, Morley LC, Misso M, *et al.*: The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. *Hum Reprod Update.* 2016; 22(6): 687–708.
50. Yang PK, Hsu CY, Chen MJ, *et al.*: The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome. *J ClinEndocrinolMetab.* 2018; 103(3):890–9.

51. Morley LC, Tang T, Yasmin E, *et al.*: Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligomenorrhea and subfertility. *Cochrane Database SystRev*2017; 11: CD003053.
52. Pedersen AJT, Stage TB, Glintborg D, *et al.*: The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. *Basic Clin Pharmacol Toxicol.* 2018; 122(2):239–
53. Saini N, Sodhi RK, Bajaj L, *et al.*: Intravaginal administration of metformin hydrochloride loaded cationic niosomes amalgamated with thermosensitive gel for the treatment of polycystic ovary syndrome: *In vitro* and *in vivo* studies. *Colloids Surf B Biointerfaces.* 2016; 144:161–9.
54. Jensterle M, Kravos NA, Pfeifer M, *et al.*: A 12-week treatment with the long- acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. *HHormones (Athens).* 2015; 14(1):81–90.
55. Graff SK, Mario FM, Ziegelmann P, *et al.*: Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. *Int J ClinPract.* 2016; 70(6):450–61.
56. Monastra G, Unfer V, Harrath AH, *et al.*: Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
57. Bevilacqua A, Dragotto J, Giuliani A, *et al.*: Myo-inositol andD-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. *J Cell Physiol.* 2019; 234(6): 9387–9398.
58. Nordio M, Proietti E: The combined therapy with myo-inositol and D-chiro- inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. *Eur Rev Med PharmacolSci.* 2012; 16(5): 575–81.
59. Colazingari S, Treglia M, Najjar R, *et al.*: The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. *Arch Gynecol Obstet.* 2013; 288(6): 1405–11.
60. Mendoza N, Pérez L, Simoncini T, *et al.*: Inositol supplementation in women withpolycysticovarysyndromeundergoingintracytoplasmicsperminjection: a systematic review and meta-analysis of randomized controlled trials. *Reprod Biomed Online.* 2017; 35(5):529–35.
61. Jamilian M, Farhat P, Foroozanfard F, *et al.*: Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. *ClinEndocrinol (Oxf).* 2017; 87(2): 194–200.
62. Tagliaferri V, Romualdi D, Immediata V, *et al.*: Metformin vsmyoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. *ClinEndocrinol (Oxf).* 2017; 86(5): 725–30.
63. Fruzzetti F, Perini D, Russo M, *et al.*: Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). *GynecolEndocrinol.* 2016; 33(1): 39–42.
64. Eggers S, Kirchengast S: The polycystic ovary syndrome--a medical condition but also an important psychosocial problem. *CollAntropol.* 2001; 25(2): 673–85. PubMed Abstract
65. Coffey S, Bano G, Mason HD: Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form- 36 (SF-36). *GynecolEndocrinol.* 2006; 22(2): 80–6.
66. Dokras A, Clifton S, Futterweit W, *et al.*: Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Obstet Gynecol.* 2011; 117(1):145–52.
67. Dokras A: Mood and anxiety disorders in women with PCOS. *Steroids.*2012;77(4): 338–41.
68. Practice Committee of the American Society for Reproductive Medicine: Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. *FertilSteril.* 2017; 108(3):426–41.
69. Wang R, Kim BV, van Wely M, *et al.*: Treatment strategies for women with WHO group II anovulation: systematic review and

network meta-analysis. *BMJ.* 2017; 356: j138.
70. Legro RS: Ovulation induction in polycystic ovary syndrome: Currentoptions. *BestPract Res ClinObstetGynaecol.* 2016; 37: 152–9.
71. Bordewijk EM, Nahuis M, Costello MF, *et al.*: Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. *Cochrane Database SystRev.* 2017; 1:CD009090.
72. Hanem LGE, Stridsklev S, Júlíusson PB, *et al.*: Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. *J ClinEndocrinolMetab.* 2018; 103(4): 1612–21.
73. Franik S, Eltrop SM, Kremer JA, *et al.*: Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. *Cochrane Database SystRev.* 2018; 5:CD010287.
74. Rezk M, Shaheen AE, Saif El-Nasr I: Clomiphene citrate combined with metforminversusletrozoleforinductionofovulationinclomiphene-resistant polycystic ovary syndrome: a randomized clinical trial. *GynecolEndocrinol.* 2018; 34(4): 298–300.
75. Kalem MN, Kalem Z, Gurgan T: Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles. *J Endocrinol Invest.* 2017; 40(7): 745–52.
76. Salamun V, Jensterle M, Janez A, *et al.*: Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. *Eur J Endocrinol.* 2018; 179(1): 1–11.

How to cite this article: Maged MN, Mohamed MN, Shehata LH. Polycystic ovary syndrome (PCOS): current and future therapy. International Journal of Science & Healthcare Research. 2020; 5(3): 202-213.

******